High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
617.48M
+28.34%
0.052
-52.37%
656.19M
+11.98%
0.157
-21.71%
663.75M
+21.83%
0.184
+8.34%
Estimates Revision
The market is revising Upward the revenue expectations for Hims & Hers Health, Inc. (HIMS) for FY2025, with the revenue forecasts being adjusted by 0.08% over the past three months. During the same period, the stock price has changed by -17.33%.
Revenue Estimates for FY2025
Revise Upward
+0.08%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-19.9%
In Past 3 Month
Stock Price
Go Down
-17.33%
In Past 3 Month
11 Analyst Rating
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 46.25 USD with a low forecast of 30.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
6 Hold
3 Sell
Hold
Current: 40.020
Low
30.00
Averages
46.25
High
85.00
Current: 40.020
Low
30.00
Averages
46.25
High
85.00
Seaport Research
Buy
downgrade
$66 -> $59
2025-11-04
Reason
Seaport Research
Price Target
$66 -> $59
2025-11-04
downgrade
Buy
Reason
Seaport Research lowered the firm's price target on Hims & Hers to $59 from $66 and keeps a Buy rating on the shares. Quarterly results showed solid growth trends despite near term headwinds, the analyst tells investors.
BofA
Underperform
maintain
$28 -> $32
2025-11-04
Reason
BofA
Price Target
$28 -> $32
2025-11-04
maintain
Underperform
Reason
BofA raised the firm's price target on Hims & Hers to $32 from $28 and keeps an Underperform rating on the shares after the company reported a "mixed" quarter, with revenue and EBITDA exceeding Street and BofA estimates and total subscribers falling below expectations. The firm sees downside risk to 2026 consensus revenue estimates and lowered its own 2026 EBITDA estimates, but rolls its valuation framework from 2025 to 2026, yielding its increased price target.
KeyBanc
Sector Weight
initiated
$52
2025-10-21
Reason
KeyBanc
Price Target
$52
2025-10-21
initiated
Sector Weight
Reason
KeyBanc last night initiated coverage of Hims & Hers with a Sector Weight rating and no price target. The firm views Hims as a "disruptive" direct-to-consumer healthcare business. It is "intrigued" by the company's international ramp and expansion into more treatments, but believes it may lead to "more muted" margin expansion in 2026. KeyBanc's fair value estimate is $52 per share.
KeyBanc
initiated
2025-10-20
Reason
KeyBanc
Price Target
2025-10-20
initiated
Reason
KeyBanc initiated coverage of Hims & Hers with a Sector Weight rating.
Morgan Stanley
analyst
Equal Weight
maintain
$40
2025-09-15
Reason
Morgan Stanley
analyst
Price Target
$40
2025-09-15
maintain
Equal Weight
Reason
Morgan Stanley reports that third party data reveals a 22% year-over-year decline for Hims & Hers app downloads in the month of August, giving the company a four-month streak of negative growth and a decline for the sixth time in seven months. A key debate for the stock is slowing growth in the core offering and durability of growth in weight loss relative to contributions from new product introductions, such as the new testosterone offering, says the analyst. These dynamics are likely to keep Hims volatile, adds the analyst, who has an Equal Weight rating and $40 price target on the shares.
Truist
Hold
downgrade
$48 -> $37
2025-08-18
Reason
Truist
Price Target
$48 -> $37
2025-08-18
downgrade
Hold
Reason
Truist lowered the firm's price target on Hims & Hers to $37 from $48 and keeps a Hold rating on the shares. The firm's intra-quarter Truist Card Data suggests that the company's GLP-1 related revenues may step up in the quarter, with a further modest increase in Q4, largely driven by realizing deferred revenue, though its estimated revenue mix for the second half makes Truist less constructive about the y/y growth in 2026, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Hims & Hers Health Inc (HIMS.N) is 62.84, compared to its 5-year average forward P/E of 0.30. For a more detailed relative valuation and DCF analysis to assess Hims & Hers Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.30
Current PE
62.84
Overvalued PE
54.05
Undervalued PE
-53.45
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
4.34
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
44.56
Undervalued EV/EBITDA
-35.89
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.52
Current PS
0.00
Overvalued PS
6.20
Undervalued PS
0.84
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 211.82% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
HIMS News & Events
Events Timeline
(ET)
2025-12-04
07:10:00
Hims & Hers Begins Serving Customers in Canada
2025-12-03 (ET)
2025-12-03
09:10:00
Hims & Hers Health Acquires YourBio Health
2025-12-02 (ET)
2025-12-02
16:00:00
Hims & Hers Health Shares Decline, Option Traders Show Moderate Bearish Sentiment
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/4ba57b4cb15fb54e8e716f7f547181183d813e03be40f6a1792a9514e067c335.png)
Preview
8.5
00:22 AMBenzingaPinnedWhat’s Happening with Hims & Hers Health Stock on Thursday?
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/b9b2edcb8eb433367ef66d490bd2c1a7ffc7f6b814df6473552cf1add0cf1a38.png)
Preview
8.5
12-04SeekingAlphaPinnedHims & Hers Expands to Canada Following Livewell Acquisition
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/37f2bb14f77834e0152db903a02220bd2bcffc9c12d5d07a1d168d6b1980ef53.png)
Preview
8.5
12-04BenzingaPinnedHims & Hers Acquires YourBio to Offer At-Home Pain-Free Blood Testing
Sign Up For More News
People Also Watch
FAQ
What is Hims & Hers Health Inc (HIMS) stock price today?
What is Hims & Hers Health Inc (HIMS)'s business?
What is the price predicton of HIMS Stock?
What is Hims & Hers Health Inc (HIMS)'s revenue for the last quarter?
What is Hims & Hers Health Inc (HIMS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Hims & Hers Health Inc (HIMS)'s fundamentals?
How many employees does Hims & Hers Health Inc (HIMS). have?